CorTec

CorTec operates at the intersection of medical devices, neuroscience and implantable neurotechnology. Its differentiation rests on combining a proprietary, fully implantable bidirectional brain-computer interface with in-house development and manufacturing capabilities, including electrodes, hermetic packaging and electronics. The Brain Interchange platform is intended to record and stimulate neural activity, while the company also offers contract development and manufacturing services to other neurotechnology developers. This creates two related routes to market: advancing its own clinical platform and supplying components or engineering capabilities to partners. The company has a 51–100 employee band and has raised approximately $29.6 million across five recorded financing rounds, including a €2.5 million grant in 2022. FDA Breakthrough Device Designation for stroke rehabilitation and acceptance into the FDA’s advisory program are meaningful regulatory milestones, not evidence of approval. The available peer list does not identify distinct comparable companies, so specific competitors cannot be named reliably here. CorTec’s competitive position is therefore best described by its integrated implant platform, manufacturing capabilities and clinical focus, rather than by an unverified ranking against named rivals.

CorTec’s development trajectory has moved from early financing toward clinical translation of an implantable neural interface. Its recorded financing began with a Seed round of approximately $3.27 million in 2011, followed by Series A funding of about $3.97 million in 2013 and a $5.45 million Series B in 2016. A $14.25 million Series C in 2019 was the largest listed equity round, and a $2.65 million grant in December 2022 brought recorded total funding to approximately $29.6 million. The clearest operational inflection point came on Jul 29, 2025, when CorTec announced the first human implantation of Brain Interchange. In April 2026, FDA Breakthrough Device Designation for stroke rehabilitation and entry into the FDA Total Product Life Cycle Advisory Program added regulatory momentum; a report on Apr 14, 2026 also described plans for a third stroke patient implantation. The company’s 51–100 employee band and lack of specific hiring information provide limited evidence for assessing workforce expansion. Overall, the available indicators point to progress in clinical development and regulatory engagement, while commercialization, approval and subsequent financing remain unconfirmed.